|
Live online
Classroom
|
2026 |
| Jan |
Feb |
Mar |
Apr |
May |
Jun |
Jul |
Aug |
Sep |
Oct |
Nov |
Dec |
| A Practical Guide to Producing and Maintaining the PSMF |
Vigilance |
|
13 |
|
|
|
|
|
|
16 |
|
|
|
| A Practical Guide to Writing Risk Management Plans (RMPs) |
Vigilance |
|
|
20 |
|
|
|
|
|
|
19 |
|
|
| A Practical Introduction to Good Clinical Practice (GCP) |
GxP |
|
|
|
15 |
|
|
|
|
|
6 |
|
|
| AI & ML in Clinical Trials: Fundamentals, Applications, and Regulatory Aspects |
Artificial Intelligence (AI) in Life Sciences |
|
|
|
|
11 |
|
|
|
|
|
5 |
|
| AI in Pharmacovigilance |
Artificial Intelligence (AI) in Life Sciences |
|
|
|
|
18 |
|
|
|
|
|
18 |
|
| APIs in Focus: Understanding ICH, GMP and Supply Chain Excellence |
GxP |
|
|
|
29-30 |
|
|
|
|
|
21-22 |
|
|
| Achieving Publication Success in Scientific Journals |
Medical Writing |
|
|
2 |
|
|
|
|
|
21 |
|
|
|
| Additional Risk Minimization Measures (aRMMs) and Their Effectiveness |
Vigilance |
|
|
|
|
|
16 |
|
|
|
|
|
2 |
| Advanced Pharmacovigilance: From Performing Successful Due Diligence to Benefit-Risk Assessments – What to Consider |
Vigilance |
|
|
23-25 |
|
|
|
|
|
21-25 |
|
|
|
| An Essential Overview of Medical Information |
Regulatory Affairs |
|
|
|
|
|
22 |
|
|
|
|
|
3 |
| An Essential Overview of the Pharmaceutical and Biotech Industries |
Regulatory Affairs |
|
|
12 |
|
|
|
|
|
28 |
|
|
|
| An Introduction to Human Factors for Pharmaceutical and Medical Device Professionals |
Medical Devices |
|
|
|
|
8 |
|
|
|
|
|
19 |
|
| An Introduction to Signal Detection |
Vigilance |
|
|
|
16 |
|
|
|
|
|
14 |
|
|
| An Introduction to Technology Transfer for Solid Dosage Forms |
GxP |
|
|
6 |
|
|
|
|
|
18 |
|
|
|
| An Overview of EU and UK Regulatory Affairs |
Regulatory Affairs |
|
11-12 |
|
|
|
|
|
|
21-22 |
|
|
|
| An Overview of Ethical Standards in Clinical Research Publication |
GxP |
|
|
|
|
13 |
|
|
|
|
|
|
11 |
| Antimicrobial Resistance (AMR) and 'One Health': Current Challenges, Regulatory Frontiers and Future Solutions |
Regulatory Affairs |
|
|
|
|
|
10 |
|
|
|
|
|
9 |
| Behavioural Risk Management in Clinical Trials |
Clinical Research |
|
|
|
13 |
|
|
|
|
|
5 |
|
|
| Best Practice for Writing Effective SOPs |
Regulatory Affairs |
|
|
26 |
|
|
|
14 |
|
|
|
26 |
|
| Best Practices for Supplier Qualification in Life Science |
Medical Devices |
|
|
|
|
6-7 |
|
|
|
|
|
12-13 |
|
| Biosimilars |
Biopharma |
|
|
16-17 |
|
|
|
|
|
22-23 |
|
|
|
| Biotechnology for the Non-Biotechnologist |
Biopharma |
|
|
|
|
|
10-12 |
|
|
|
|
30-4 |
|
| Building The Business Case For Pharma 4.0 |
Medical Technology |
|
|
|
13 |
|
|
|
|
|
6 |
|
|
| CAPA (Corrective and Preventative Action) |
Regulatory Affairs |
|
|
|
|
|
15 |
|
|
|
|
|
4 |
| Chemistry, Manufacture and Control (CMC) - Regulatory Requirements for Biological Drug Products |
GxP |
|
|
|
23-24 |
|
|
|
|
|
19-20 |
|
|
| Cleaning Validation - Best Practice in Pharmaceuticals |
GxP |
|
|
|
|
|
23-24 |
|
|
|
|
|
1-2 |
| Clinical & Post-Marketing Safety |
Vigilance |
|
|
|
|
11-12 |
|
|
|
|
|
16-17 |
|
| Clinical Overview and Clinical Summary: Creating Effective Marketing Authorisation Application |
Regulatory Affairs |
|
|
16-17 |
|
|
|
|
|
30-1 |
|
|
|
| Clinical Quality Management Systems |
Clinical Research |
|
|
23-24 |
|
|
|
|
|
17-18 |
|
|
|
| Clinical Research Project Management |
Medical Devices |
|
|
|
29-1 |
|
|
|
|
|
21-23 |
|
|
| Clinical Trial Agreements: Key Legal, Regulatory and IP Considerations for the EU and UK Markets |
Commercial Contracts |
|
|
18 |
|
|
|
2 |
|
|
|
24 |
|
| Clinical Trial Monitoring |
Clinical Research |
|
|
|
|
|
18-19 |
|
|
|
|
|
10-11 |
| Clinical Trial Regulatory Requirements |
Clinical Research |
|
|
2-3 |
|
|
|
|
|
14-15 |
|
|
|
| Clinical Trials in the MENA Region |
Clinical Research |
|
|
|
|
6 |
|
|
|
|
|
11 |
|
| Competition Law for the Pharmaceutical Industry |
Commercial Contracts |
|
27 |
|
|
|
|
|
|
|
|
|
|
| Cosmetovigilance |
Cosmetics |
|
|
|
|
|
18-19 |
|
|
|
|
|
8-9 |
| Data Integrity Auditor Masterclass |
GxP |
|
|
|
22-23 |
|
|
|
|
|
14-15 |
|
|
| Data Integrity and Document Management |
Medical Devices |
|
|
|
|
|
22 |
|
|
|
|
|
8 |
| Dealing With Scientific Journal Reviewers: From Comments to Resubmission |
Medical Devices |
|
|
|
|
|
15 |
|
|
|
|
|
1 |
| Development of Combination Products: Critical Interactions |
GxP |
|
|
|
|
|
|
|
|
16-17 |
|
|
|
| Digital CMC |
Medical Technology |
|
|
|
|
6 |
|
|
|
|
|
2 |
|
| Digital CMC: The Key To Realising Pharma 4.0 |
GxP |
|
|
|
|
|
23 |
|
|
|
|
|
4 |
| Digital Technology Transfers |
Medical Technology |
|
|
4 |
|
|
|
|
|
22 |
|
|
|
| Digital Technology and Personalisation in Patient Support Programmes |
Clinical Research |
|
|
|
|
6 |
|
|
|
|
|
4 |
|
| Drafting Commercial Contracts for the Pharmaceutical Industry |
Commercial Contracts |
|
|
|
|
20-21 |
|
|
|
|
|
11-12 |
|
| EU Pharmaceutical Regulations and Strategy |
Regulatory Affairs |
|
|
2-3 |
|
|
|
|
|
|
5-6 |
|
|
| EU Proposed Pharmaceutical Legislation Changes |
Regulatory Affairs |
|
|
|
|
|
|
1 |
|
|
|
|
|
| Effective Change Management in Pharma |
GxP |
|
|
|
17 |
|
|
|
|
|
9 |
|
|
| Effective Communication & Negotiation in Technology Transfers |
GxP |
|
|
|
|
18 |
|
|
|
|
15 |
|
|
| Effective Deviation Management Systems in Pharma |
GxP |
|
|
20 |
|
|
|
|
|
25 |
|
|
|
| Effective Regulatory Compliance for Storage and Distribution in Pharma Supply Chains |
GxP |
|
|
|
|
15 |
|
|
|
|
|
20 |
|
| Effective Technical Writing & Editing |
Medical Writing |
|
|
|
|
15 |
|
|
|
|
|
18 |
|
| Ensuring Clinical Research Quality & Patient Safety |
GxP |
|
|
|
|
|
|
|
|
14 |
|
|
|
| Essential Documentation Skills for Clinical Research Compliance |
GxP |
|
|
9 |
|
|
|
|
|
|
5 |
|
|
| GCP and Clinical Research Update: What Inspectors Are Focusing on Now |
Clinical Research |
|
|
|
|
19 |
|
|
|
|
|
20 |
|
| GMP Principles in Vaccine Manufacturing |
GxP |
|
|
|
|
|
16-17 |
|
|
|
|
|
8-9 |
| Golden Rules of Being a Successful GMP Auditor |
GxP |
|
|
|
|
|
|
|
|
30-1 |
|
|
|
| Good Distribution Practices of Pharmaceuticals and APIs |
GxP |
|
|
|
|
14-15 |
|
|
|
|
|
16-17 |
|
| Good Writing Practice for Clinical Research: Ethics, Standards & Compliance |
GxP |
|
|
|
20 |
|
|
|
|
|
|
18 |
|
| How to Audit Pharmaceutical Suppliers (Material and Service) |
GxP |
|
26-27 |
|
|
|
|
|
|
14-15 |
|
|
|
| How to Deal with Difficult Situations in GMP Audits |
GxP |
|
|
5 |
|
|
|
|
|
28 |
|
|
|
| How to Interview During GMP Audits |
GxP |
|
|
12 |
|
|
|
|
|
24 |
|
|
|
| How to Manage Internal GMP Audits |
GxP |
|
24-25 |
|
|
|
|
|
|
21-22 |
|
|
|
| How to Pass International Health Authority Inspections |
GxP |
|
|
|
16-17 |
|
|
|
|
|
7-8 |
|
|
| How to Perform Bullet-Proof Good Distribution Practices (GDP) and Good Storage Practices (GSP) Audits |
GxP |
|
|
|
|
|
18-19 |
|
|
|
|
|
10-11 |
| Literature Searching in Drug Safety |
Vigilance |
|
|
|
|
14-15 |
|
|
|
|
|
10-11 |
|
| Managing Service Providers including CRO and CMOs oversight to comply with ICH GCP R3 |
Animal Health |
|
|
|
13-14 |
|
|
|
|
|
15-16 |
|
|
| Mastering CTD Submissions in the MENA Region |
Regulatory Affairs |
|
|
|
|
19 |
|
|
|
|
|
26 |
|
| Mastering Computer System Validation |
GxP |
|
|
|
|
|
17-18 |
|
|
|
|
|
10-11 |
| Mastering Ethical and Effective Scientific Publishing: Applying Good Publication Practice (GPP) |
Medical Writing |
|
|
|
|
|
|
8 |
|
|
|
|
|
| Mastering Grant Writing: Essential Skills for Crafting Winning Proposals |
Medical Writing |
|
|
|
|
|
22-23 |
|
|
|
|
|
8-9 |
| Measuring Performance in Clinical Research Management |
Clinical Research |
|
|
|
|
6 |
|
|
|
|
|
23 |
|
| Medical Editing for Peer-Reviewed Journals |
Medical Writing |
|
|
|
|
8 |
|
|
|
|
|
4 |
|
| Medical Writing Excellence: Crafting Compelling Scientific Documents |
Medical Writing |
|
|
|
|
|
|
|
|
30-1 |
|
|
|
| Medical Writing for Consumers |
Medical Writing |
|
|
|
21 |
|
|
|
|
|
1 |
|
|
| Medical Writing with AI |
Artificial Intelligence (AI) in Life Sciences |
|
|
|
|
|
18 |
|
|
|
|
|
8 |
| Microbiomics in Clinical Trials |
Clinical Research |
|
26 |
|
|
|
|
|
|
14 |
|
|
|
| Molecular Biology for the Non-Molecular Biologist |
Biopharma |
|
|
|
20-21 |
|
|
|
|
|
8-9 |
|
|
| Navigating EU and FDA Regulations for Drug/Device and Device/Drug Combination Products |
Medical Devices |
|
|
2-3 |
|
|
|
|
|
14-15 |
|
|
|
| Navigating ICH GCP E6 (R3): What You Need to Know |
Clinical Research |
29 |
|
|
|
|
|
13 |
|
|
|
|
|
| New EU GMP Annex 1: Compliant Sterile Medicinal Products |
GxP |
|
|
|
|
19-21 |
|
|
|
|
|
24-26 |
|
| Orphan Drug Regulatory Masterclass: EU & US Insights |
Regulatory Affairs |
|
|
4 |
|
|
|
|
|
|
6 |
|
|
| Pharmaceutical Development of ATMPs |
GxP |
|
|
18-19 |
|
|
|
|
|
28-29 |
|
|
|
| Pharmaceutical Packaging Essentials: From Regulatory Compliance to Market Success |
GxP |
26-28 |
|
|
|
|
|
|
|
22-24 |
|
|
|
| Pharmaceutical Regulatory Affairs in Africa |
Regulatory Affairs |
|
|
|
|
6-7 |
|
|
|
|
|
3-4 |
|
| Pharmaceutical Regulatory Affairs in Asia |
Regulatory Affairs |
|
|
24-26 |
|
|
|
|
|
|
20-22 |
|
|
| Pharmaceutical Regulatory Affairs in China |
Regulatory Affairs |
|
|
|
|
|
3-4 |
|
|
|
|
25-26 |
|
| Pharmaceutical Regulatory Affairs in Russia, Eurasian Union and the CIS |
Regulatory Affairs |
|
|
5-6 |
|
|
|
|
|
30-1 |
|
|
|
| Pharmaceutical Regulatory Affairs in the Middle East |
Regulatory Affairs |
|
24-25 |
|
|
|
|
|
|
|
20-21 |
|
|
| Pharmaceutical Regulatory Affairs in the Middle East and North Africa |
Regulatory Affairs |
|
|
|
|
|
2-4 |
|
|
|
|
|
|
| Pharmacovigilance Aspects of Licensing Agreements |
Vigilance |
|
|
|
|
|
25 |
|
|
|
|
|
10-11 |
| Pharmacovigilance QMS & Inspection Preparation |
Vigilance |
|
|
|
27-28 |
|
|
|
|
|
8-9 |
|
|
| Pharmacovigilance: An Overview of Drug Safety from Safety Collection to Regulatory Inspection |
Vigilance |
|
|
|
30 |
|
|
|
|
|
5-6 |
|
|
| Practical Requirements of the Arab Pharmacovigilance Guidelines |
Vigilance |
|
|
|
21-22 |
|
|
|
|
|
21-22 |
|
|
| Protein Engineering for Pharmaceutical Biotechnology |
Biopharma |
|
|
|
|
|
|
7-8 |
|
|
|
|
|
| Real World Evidence (RWE), Real World Data (RWD) and the Application of Artificial Intelligence (AI) in Pharma |
Artificial Intelligence (AI) in Life Sciences |
|
|
|
|
|
22 |
|
|
|
|
|
2 |
| Risk Evaluation and Mitigation Strategies (REMS) vs Risk Management Plans (RMP) |
Vigilance |
|
12 |
|
|
|
|
|
|
14 |
|
|
|
| Selecting the Best Scientific Journal for Your Research |
Medical Devices |
|
|
|
13 |
|
|
|
|
|
19 |
|
|
| Signal Detection and Regulatory Expectations |
Vigilance |
|
2-3 |
|
|
|
|
|
|
30-1 |
|
|
|
| Signal Detection: A Comprehensive Introduction |
Vigilance |
|
|
|
|
|
|
1 |
|
|
|
|
|
| Smart Packaging and Electronic Patient Information |
Medical Devices |
|
|
|
|
15 |
|
|
|
|
|
2-3 |
|
| Software Automation in Research and Development (R&D) Clinical Trials |
Clinical Research |
|
|
17 |
|
|
|
|
|
28 |
|
|
|
| Stability Testing of Pharmaceuticals and Biopharmaceuticals |
GxP |
|
|
|
|
20-22 |
|
|
|
|
|
9-11 |
|
| Successful Cognitive Testing in Clinical Drug Trials: Biomarkers, Test Selection & Integration |
Clinical Research |
|
|
16 |
|
|
|
|
|
18 |
|
|
|
| Successful Medical Writing – from Protocol to CTD |
Medical Writing |
|
|
23-24 |
|
|
|
|
|
22-23 |
|
|
|
| The 2024 EU AI Act |
Artificial Intelligence (AI) in Life Sciences |
|
|
|
|
|
23 |
|
|
|
|
|
3 |
| The Applications of Nanoparticles in the Pharmaceutical and Biomedical Industries |
Biopharma |
|
|
11-12 |
|
|
|
|
|
15-16 |
|
|
|
| The Common Technical Document |
GxP |
|
|
|
|
14-15 |
|
|
|
|
21-22 |
|
|
| The FDA Drug Approval Process |
Regulatory Affairs |
|
23-24 |
|
|
|
|
|
|
24-25 |
|
|
|
| The Principles & Applications of CRISPR |
Biopharma |
|
|
|
|
|
|
7 |
|
|
|
|
|
| The Regulatory Requirements on Nitrosamines in the Pharmaceutical Industry |
Regulatory Affairs |
|
|
|
20-21 |
|
|
|
|
|
12-13 |
|
|
| Thinking Outside of the GMP Box |
GxP |
|
|
|
|
|
|
|
|
16-17 |
|
|
|
| US FDA - Understanding Key Factors When Working with the FDA |
Biopharma |
|
|
|
|
12 |
|
|
|
|
|
25 |
|
| Understanding Scientific Journal Submission and Publication |
Medical Devices |
|
|
|
|
11 |
|
|
|
|
|
16 |
|
| Understanding Toxicology: A Guide for Non-Toxicologists |
Regulatory Affairs |
|
|
|
|
|
|
15 |
|
|
|
|
|
| Upstream and Downstream Manufacturing in the Biopharmaceutical Industry |
GxP |
|
|
|
|
|
11 |
|
|
|
|
18 |
|
| Utilising Patient Adherence Data and Digital Tools to Improve Patient Outcomes |
Clinical Research |
|
|
|
16 |
|
|
|
|
|
13 |
|
|
| Variations to Marketing Authorisations |
Regulatory Affairs |
|
|
|
|
|
2-3 |
|
|
|
|
11-12 |
|